CA3201129A1 - Material and method for treating cancer - Google Patents
Material and method for treating cancerInfo
- Publication number
- CA3201129A1 CA3201129A1 CA3201129A CA3201129A CA3201129A1 CA 3201129 A1 CA3201129 A1 CA 3201129A1 CA 3201129 A CA3201129 A CA 3201129A CA 3201129 A CA3201129 A CA 3201129A CA 3201129 A1 CA3201129 A1 CA 3201129A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- cancer
- component
- composition according
- mitomycin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063124111P | 2020-12-11 | 2020-12-11 | |
| US63/124,111 | 2020-12-11 | ||
| PCT/IB2021/061499 WO2022123480A1 (en) | 2020-12-11 | 2021-12-09 | Material and method for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3201129A1 true CA3201129A1 (en) | 2022-06-16 |
Family
ID=78916713
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3201129A Pending CA3201129A1 (en) | 2020-12-11 | 2021-12-09 | Material and method for treating cancer |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US12336979B2 (https=) |
| EP (1) | EP4259093B1 (https=) |
| JP (1) | JP2023553976A (https=) |
| KR (1) | KR20230118632A (https=) |
| CA (1) | CA3201129A1 (https=) |
| WO (1) | WO2022123480A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10471150B2 (en) | 2010-01-20 | 2019-11-12 | Urogen Pharma Ltd. | Material and method for treating internal cavities |
| US12336979B2 (en) | 2020-12-11 | 2025-06-24 | Urogen Pharma Ltd. | Material and method for treating cancer |
| US20240100019A1 (en) * | 2022-09-28 | 2024-03-28 | Urogen Pharma Ltd. | Compositions comprising a thermoreversible hydrogel, and having an extended in-use period |
| EP4713013A1 (en) | 2023-05-16 | 2026-03-25 | UroGen Pharma Ltd. | Immunomodulating treatments of body cavities |
| KR20260043121A (ko) | 2023-07-25 | 2026-03-31 | 우로젠 파마 엘티디. | 미토마이신을 함유하는 열 겔화 제약 조성물을 사용한 저등급 중간-위험 비근침습성 방광암의 치료 |
| CN121729785A (zh) | 2023-09-06 | 2026-03-24 | 株式会社Lg新能源 | 袋用片材、袋型电池盒以及用于制造电池盒的方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0386960A3 (en) | 1989-03-07 | 1991-10-23 | American Cyanamid Company | Pharmaceutical compositions useful as drug delivery vehicles and/or as wound dressings |
| US5861174A (en) | 1996-07-12 | 1999-01-19 | University Technology Corporation | Temperature sensitive gel for sustained delivery of protein drugs |
| US6286513B1 (en) | 1998-10-22 | 2001-09-11 | Jessie L. Au | Methods for treating superficial bladder carcinoma |
| US20040009212A1 (en) | 2002-01-30 | 2004-01-15 | Pharma Power Biotec Co. Ltd. | Mucoadhesive thermoresponsive medicament-carrier composition |
| GB0328060D0 (en) | 2003-12-04 | 2004-01-07 | Sod Conseils Rech Applic | Botulinum toxin treatment |
| GB0414825D0 (en) | 2004-07-02 | 2004-08-04 | Biostatus Ltd | Gel formulations and uses thereof |
| US20090142259A1 (en) | 2006-05-12 | 2009-06-04 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of bladder and urinary tract tumors |
| US9107815B2 (en) | 2008-02-22 | 2015-08-18 | Allergan, Inc. | Sustained release poloxamer containing pharmaceutical compositions |
| EP2313122B1 (en) | 2008-07-17 | 2019-03-06 | Micell Technologies, Inc. | Drug delivery medical device |
| US10471150B2 (en) | 2010-01-20 | 2019-11-12 | Urogen Pharma Ltd. | Material and method for treating internal cavities |
| ES2732150T3 (es) * | 2010-01-20 | 2019-11-20 | Urogen Pharma Ltd | Material y método para tratar cavidades internas |
| EP2734187B1 (en) * | 2011-07-20 | 2018-09-05 | UroGen Pharma Ltd. | Materials and method for treating internal body cavities |
| US20140142191A1 (en) | 2011-07-20 | 2014-05-22 | Theracoat Ltd. | Production of thermoreversible hydrogels for therapeutic applications |
| PT2865391T (pt) * | 2013-10-22 | 2017-12-22 | Medac Ges Für Klinische Spezialpräparate Mbh | Processo para a produção de uma composição farmacêutica liofilizada com um conteúdo de mitomicina c |
| US9801854B1 (en) * | 2014-01-17 | 2017-10-31 | Urogen Pharma Ltd. | Slow release formulations of cell cycle regulators and anti-cancer agents for local treatment of solid cancer |
| WO2016004213A2 (en) | 2014-07-01 | 2016-01-07 | Vicus Therapeutics, Llc | Hydrogels for treating and ameliorating cancers and potentiating the immune system and methods of making and using them |
| US20170128424A1 (en) | 2015-11-11 | 2017-05-11 | Qrono, Inc. | Sustained release pharmaceutical compositions and methods of use |
| JP7265989B2 (ja) * | 2016-10-25 | 2023-04-27 | ウロゲン ファーマ リミテッド | 体腔の免疫調節治療 |
| WO2018169960A1 (en) | 2017-03-17 | 2018-09-20 | The Johns Hopkins University | Nanoparticle formulations for enhanced drug delivery to the bladder |
| EP3498270A1 (en) * | 2017-10-30 | 2019-06-19 | Urogen Pharma Ltd. | Slow release formulations of cell cycle regulators and anti-cancer agents for local treatment of solid cancer |
| US12336979B2 (en) | 2020-12-11 | 2025-06-24 | Urogen Pharma Ltd. | Material and method for treating cancer |
-
2021
- 2021-12-09 US US17/546,204 patent/US12336979B2/en active Active
- 2021-12-09 EP EP21824683.3A patent/EP4259093B1/en active Active
- 2021-12-09 JP JP2023535631A patent/JP2023553976A/ja active Pending
- 2021-12-09 WO PCT/IB2021/061499 patent/WO2022123480A1/en not_active Ceased
- 2021-12-09 KR KR1020237023151A patent/KR20230118632A/ko active Pending
- 2021-12-09 CA CA3201129A patent/CA3201129A1/en active Pending
-
2023
- 2023-12-11 US US18/535,108 patent/US12171747B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230118632A (ko) | 2023-08-11 |
| JP2023553976A (ja) | 2023-12-26 |
| US20240108603A1 (en) | 2024-04-04 |
| EP4259093A1 (en) | 2023-10-18 |
| EP4259093B1 (en) | 2025-08-13 |
| US20220202773A1 (en) | 2022-06-30 |
| US12171747B2 (en) | 2024-12-24 |
| US12336979B2 (en) | 2025-06-24 |
| WO2022123480A1 (en) | 2022-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12171747B2 (en) | Material and method for treating cancer | |
| EP2525777B1 (en) | Material and method for treating internal cavities | |
| US20220118096A1 (en) | Material and method for treating internal cavities | |
| US7875677B2 (en) | Micellar drug delivery systems for hydrophobic drugs | |
| JP2021506913A (ja) | 液体送達組成物 | |
| JP2001526246A (ja) | 薬剤送達及び／又は癒着防止のための方法及び組成物 | |
| KR20180103039A (ko) | 방광암 치료용 제제 | |
| CN1861041B (zh) | 局部注射用温敏型缓释凝胶剂及制备方法 | |
| CN116099007A (zh) | 一种局麻药与生物碱的帕莫酸盐缓释组合物 | |
| KR102455423B1 (ko) | 펜벤다졸 가용화 조성물 및 이의 용도 | |
| KR20190084284A (ko) | 상부요로상피암종의 치료 방법 | |
| KR101010411B1 (ko) | 온단세트론의 직장내 투여를 위한 온도 감응성 액상좌제조성물 | |
| CN1843368B (zh) | 一种灯盏花素长循环纳米脂质体及其制备方法 | |
| WO2024194781A1 (en) | Improved compositions | |
| KR102377334B1 (ko) | 핀골리모드 유도체 화합물의 가용화 조성물 및 이의 용도 | |
| TW202400169A (zh) | 藥學組合物及其製備方法 | |
| WO2025153747A1 (es) | Composiciones y esquemas de dosificación de inhibidores de aromatasa mejorados | |
| HK1063742B (en) | Micellar drug delivery systems for hydrophobic drugs | |
| AU2002249045A1 (en) | Micellar drug delivery systems for hydrophobic drugs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241128 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241128 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241128 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251128 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251128 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20251205 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20251205 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251205 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260203 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260203 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260203 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260203 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260203 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260205 |